Table 1.
Clinical characteristics of patients with metastatic prostate cancer (mPC) or bPC stratified by circulating tumor cell (CTC) status.
| Cohort 1 (mPC) | Cohort 2 (bPC) | ||||
|---|---|---|---|---|---|
| CTC Status | CTC Status | ||||
| Positive | Negative | p= | Positive | Negative | |
| n (%) | 9 (40.9) | 13 (59.1) | <0.001 | 5 (100) | 0 (0.00) |
| Time FU (month, median [IQR]) |
77.6 [52.6, 82.5] | 46.6 [30.2, 76.9] | |||
| Age (yr, median [IQR]) | 66.9 [59.2, 75.4] | 66.8 [63.9, 73.9] | 0.85 | 65.8 [57.4, 74.7] | |
| T stage (%) | 0.72 * | ||||
| cT2 | 1 (11.1) | 1 (7.7) | |||
| cT3 | 6 (66.7) | 7 (53.8) | |||
| cT4 | 2 (22.2) | 5 (38.5) | |||
| pT2 | 2 (40.0) | ||||
| pT3 | 3 (60.0) | ||||
| Gleason grade group (%) | 0.61 ** | ||||
| 2 + 3 | 0 (0.00) | 0 (0.00) | 3 (60.0) | ||
| 4 | 3 (33.3) | 2 (14.3) | 1 (20.0) | ||
| 5 | 6 (66.7) | 11 (84.6) | 1 (20.0) | ||
| PSA values (ng/mL, median [IQR]) |
|||||
| PSA at diagnosis | 26.0 [12.0, 72.0] | 33.0 [12.0, 58.0] | 0.95 | ||
| PSA after ADT | 1.10 [0.40, 7.60] | 3.00 [0.60, 9.20] | 0.66 | ||
| PSA at relapse | 0.26 [0.20,0.54] | ||||
| Time ADT/DC01 (mo., median [IQR]) |
3.42 [1.74, 3.72] | 2.30 [1.64, 4.77] | 0.92 | ||
| Time RP/DC01 (mo., median [IQR]) |
13.2 [7.02, 14.5] | ||||
| No. reactive peptides in IR (%) | 0.009 * | ||||
| 0 | 0 (0.0) | 3 (23.1) | |||
| 1 | 1 (11.1) | 6 (46.2) | |||
| 2 | 5 (55.6) | 3 (23.1) | |||
| 3 | 3 (33.3) | 1 (7.7) | |||
ADT: Androgen-deprivation therapy; IQR: interquartile range; FU: follow-up; IR: immune reaction; mo.: months; PSA: prostate-specific antigen; RP: radical prostatectomy; yr: years. * Chi-square test, ** Fisher’s exact test.